Antiemetic treatment of chemotherapy-induced nausea in ovarian carcinoma patients.
In a prospective, randomized, double-blind trial the combination betamethasone-dixyrazine was compared with high-dose metoclopramide as antiemetic treatment during combination chemotherapy (melphalan-doxorubicin and cisplatin) of ovarian carcinoma. Of 40 evaluable patients, 15 (38%) had previous experience with chemotherapy. Efficacy and side effects were recorded on patient and nurse questionnaires using the visual analog scale. Nausea and vomiting were prevented in 55% of the patients treated with melphalan-doxorubicin (Day 1) and in 36% of the patients treated with cisplatin (Day 2). Betamethasone-dixyrazine was superior to high-dose metoclopramide and prevented nausea in 76% compared to 32% during melphalan-doxorubicin therapy. Akathisia was noted in 21% and acute dystonic reactions in 2.6% during metoclopramide treatment but not in any case during betamethasone-dixyrazine therapy.
Sorbe
B
B
Department of Gynecologic Oncology, Orebro Medical Center, Sweden.
Hallén
C
C
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001623:Betamethasone / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D004317:Doxorubicin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008558:Melphalan / Q000008:administration & dosage; D008787:Metoclopramide / Q000627:therapeutic use*; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010640:Phenothiazines / Q000627:therapeutic use*; D011446:Prospective Studies; D011897:Random Allocation
D014150:Antipsychotic Agents; D010640:Phenothiazines; C012950:dixyrazine; D004317:Doxorubicin; D001623:Betamethasone; D008787:Metoclopramide; D002945:Cisplatin; D008558:Melphalan